Figure 5 indicated that the TMB of patients with TP53, TTN, RYR2, LRP1B, FSIP2, and SPTA1 mutations was significantly higher than that of patients without these mutations for both NSCLC and SCLC. Here, FSIP2 is linked to non-small cell lung carcinoma.